Korea United Pharm Inc.

KOSE:A033270 Stock Report

Market Cap: ₩350.1b

Korea United Pharm Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Korea United Pharm's performance over the last few years.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2015

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Korea United Pharm has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown

How Korea United Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A033270 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 15161,43720,02155,1264,155
30 Jun 15159,14020,40052,9814,176
31 Mar 15157,74419,25153,5474,034
31 Dec 14155,19018,37552,5773,989
30 Sep 14149,47816,54752,0523,587
30 Jun 14143,56813,45251,5733,560
31 Mar 14141,91713,45051,3693,488
31 Dec 13136,89112,21249,6343,005
30 Sep 13132,85312,72648,1392,480
30 Jun 13134,12213,78549,2551,987

Quality Earnings: Insufficient data to determine if A033270 has high quality earnings.

Growing Profit Margin: Insufficient data to determine if A033270's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A033270's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare A033270's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if A033270's earnings growth over the past year exceeded the Pharmaceuticals industry average.

Return on Equity

High ROE: A033270 has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.